CoRegen Inc.

About CoRegen Inc.

CoRegen Science is a biotech company focused on eradicating cancer through groundbreaking immune system therapies. Their mission is to transform lives globally by harnessing award-winning scientific innovations to develop accessible outpatient treatments that eliminate cancer without toxicity.

Products & Services

CoRegen-engineered Tregs:A proprietary therapy involving the modification of Treg cells by knocking out a single gene to enable the immune system to target and eradicate cancer cells, showing promising pre-clinical results with no toxicity or inflammation.

Specialties

Cancer immunotherapy Molecular endocrinology Steroid receptor coactivators (SRCs) Gene modification in Treg cells

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Private Placement T: - FT: Private Placement	A: 93390000 MR: - FA: $93,390,000 FAN: 93390000	D: 2025-07-09 FD: 2025-07-09	1 investors

Private Placement Latest

2025-07-09

$93.4M

1 investor (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

S

Suneet Varma

Chairman of the Board

B

Bert W O'Malley, MD

Inventor & Principal Scientist, Board Member

S

Steve Gorlin

Vice Chairman & President

S

Sonal Gupta, M.D., Ph.D.

Chief Medical Officer

D

David Lonard, PhD

Chief Science Officer

S

Sang Jun Han, PhD

Director of Laboratory Research

View 19 more team members with Pro

Unlock Full Team Directory

Recent News

CoRegen Inc. Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised